GLP3-R/CAGRILINITIDE BLEND

GLP3-R, 12.5MG and Cagrilinitide, 2.5MG

Please note that this blend is only appropriate for those who are new to GLP3-R, and/or those who are not transferring from high dose of another GLP. This is because the ratio of GLP3-R to Cagrilinitide is 1mg of GLP3-R to 200mcg of Cagrilinitide. Because Cagri is extremely potent and must be introduced “low and slow,” it is important to beware that if you are already using GLP3-R, you will have to decrease to a 1mg dose while you get used to the Cagrilinitide. Therefore those who are already established on GLP3-R should purchase the two peptides separately rather than using the blend.

Dose once every 7 days

Stay on each dose for a minimum of 4 weeks, whether you are making progress or not during that period.

You may dose any time of the day or night, but it is preferred (not required) that you select a time that you can be consistent with from week to week

You do not have to be fasted to take this blend

Cycling of this blend is recommended



You will start at the Initial Dose of 12 units, and remain on this dose for 4 weeks. After week 4’s dose, evaluate your progress. If you are not suffering from severe adverse side effects AND are getting satisfactory appetite suppression from the initial dose, continue to take that dose until it is well-tolerated and appetite suppression wanes. Then go to 2nd dose.

Initial Dose (Weeks 1-4): Take 12 units (1mg GLP3-R, 200mcg Cagrilinitide), once every 7 days, for a minimum of 4 weeks

2nd Dose (Weeks 5-8 or ?): Take 36 units (3mg GLP3-R, 600mcg Cagrilinitide) once every 7 days, for a minimum of 4 weeks. After week 8’s dose, evaluate your progress. If you are not suffering from severe adverse side effects AND are getting satisfactory appetite suppression from the initial dose, continue to take that dose until it is well-tolerated and appetite suppression wanes. If you increase your dose at week 5, you will complete your first blend vial at week 7, and from there should transition to using the GLP3-R and Cagrilinitide in separate vials, so that you can cycle the Cagrilinitide on and off in order to prevent the body from creating anti-Cagrilinitide antibodies.